Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Metal & realty in limelight
Mon, 29 Dec 01:30 pm

Indian share markets continued to remain buoyant in the post-noon trading session. All the sectoral indices are trading in the green. Metal and realty stocks are the biggest gainers today.

BSE-Sensex is up 180 points and NSE-Nifty is trading 52 points up. BSE Mid Cap is trading 0.9% up and BSE Small Cap index is trading up by 0.7%. The rupee is trading at 63.61 to the US dollar.

Majority of the engineering stocks are trading firm led by Everest Kanto Cylinder and Jindal Drilling. As per a leading financial daily, Larsen & Toubro's (L&T's) subsidiary L&T Hydrocarbon Engineering has won an offshore contract worth Rs 8.9 bn from Oil & Natural Gas Corporation (ONGC). The contract is for the additional development of the Vasai East project to improve its recovery rate. The Vasai East project had commenced production in 2008. The project is expected to be completed by April 2016. L&T stock is presently trading up 0.7%.

Most of the domestic pharma stocks are trading in the green with Ranbaxy laboratories and Lupin being the biggest gainers. As per a leading financial daily, Lupin is on the look-out for acquisitions in markets of US, Europe (Russia, Turkey), Latin America, Japan and China to widen its overseas presence. The company is eyeing suitable acquisitions in the inhalation, complex injectables and derma space. In FY14, international operations formed 75% of the overall revenues for the company out of which the US markets alone accounted for a lion's share of 44%. The company expects the US generics business to remain a principal growth driver with 15-20 generic product launches lined up over the next 12-15 months. Lupin presently has 200 abbreviated new drug applications (ANDA) filings with US Food & Drug Administration (USFDA) out of which 100 are pending approvals and 30 are exclusive first to file. The company has also signed various agreements in the US market in FY14. The company expects its third largest business in Japan to grow by 15-20% in future.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Metal & realty in limelight". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.